Covid-19 Research

Article Figures

Refluward® HA: Efficacy and Safety in Patients with Gastro-Esophageal Diseases

View article figures, article metadata, topics, DOI, abstract, and related articles from the JBRES article record.

View Abstract Article Library
Refluward® HA: Efficacy and Safety in Patients with Gastro-Esophageal Diseases
jbres2218-g001.webp

Article Figures

Abstract

<p>The physiological activity of stomach and esophagus is often impaired by the onset of various diseases such as Gastroesophageal Reflux Disease (GERD), esophagitis, hiatal hernia, tertiary esophageal waves, Barrett’s esophagus, achalasia, gastritis, peptic ulcers, esophageal and gastric cancer.<br><br>These pathologies present different symptomatology that could be classified as gastro-esophageal and extra gastro-esophageal and the current pharmacological treatments are poor in providing comprehensive therapeutic support with good efficacy and safety.<br><br>Refluward® HA is an innovative nutraceutical formulation with two patented technologies named WARDIMIX® and MUCEDIG®. A total of 40 patients suffering of four different conditions correlated with gastro-esophageal area such as gastro-esophageal reflux, reflux esophagitis, hiatal hernia and tertial esophageal waves with both typical and atypical GERD symptomatology were enrolled in the present retrospective clinical survey.<br><br>Refluward® HA oral administration after one month reduced the total symptomatology of gastro-esophageal diseases according to two different questionnaire used RSI and GIS score. Moreover, continuing the therapy up to 3 months, a further reduction in the symptomatology was obtained without any side effect or drop out. More consistent randomized and placebo-controlled studies considering also plasmatic or endoscopic data are necessary to confirm Refluward® HA as a novel therapeutic potential treatment for different gastro-esophageal diseases.<br></p>

Similar Topic Articles

  • Combined Dopaminergic Drugs to Treat Pyoderma Gangrenosum
    Jerome H Check* and Diane L Check
    Published: 2026-03-31
    Abstract PDF DOI
  • Formulation Development, Analytical Validation and In vitro Assessment of a Generic Lymecycline 408 mg Hard Capsule
    Ali Raza, Noor Zulfi qar*, Yameen HM, Fatima A, Rizwan M, Mahmood I, Ain QU and Imran M
    Published: 2026-03-09
    Abstract PDF DOI
  • Poly-De-Prescribing to Treat the Iatrogenic Epidemic of Polypharmacy - A Major Public Health Challenge
    Garfinkel D
    Published: 2026-01-20
    Abstract PDF DOI
  • Quercetin Analogs as Cancer Chemopreventive Agents: A New Perspective
    Aliabadi A, Mahboubi RM, Bayat L, Hakimimofrad R, Ghobadi K, Omidifard N, Chaman A, Bayanati M and Zarghi A*
    Published: 2025-10-23
    Abstract FullText HTML PDF DOI
Publish with JBRES — Peer-reviewed, multidisciplinary Open Access with rapid review, DOI, and global visibility.
Double-Blind CrossRef DOI Discoverable
Submit Manuscript Membership